GLP-1 receptor agonists are established treatments for type 2 diabetes and obesity. Depression and anxiety disorders are common among people with diabetes and obesity, and both conditions are associated with an increased risk of psychiatric morbidity, illness-related absenteeism, self-harm, and suicide. The potential effects of GLP-1 RAs on mental health remain controversial.
Autoren
- Aneta Dehn
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Liver Cancer
Artificial Intelligence in Precision Oncology—Opportunities and Challenges
- Acute nonspecific back pain
Implementing a biopsychosocial approach
- Psychedelic-assisted therapy
Current status of PAT
- Neuropathic Pain
Evidence-Based Neuromodulation Based on Clinical Trials and Real-World Data
- Fibromyalgia Syndrome
Development, Diagnosis, Epidemiology, and Treatment of a Disease Entity
- Juvenile Idiopathic Arthritis
Early Detection and Targeted Treatment in an Interdisciplinary Setting
- Innovative Oral Treatment Options for Psoriasis: Icotrokinra and Zasocitinib
First-class immunomodulation combined with convenience—the data available so far is convincing
- Chronic hand eczema: common, long-lasting, and distressing